InflaRx N.V. (IFRX)

InflaRx N.V. (IFRX) Healthcare & Pipeline Overview

InflaRx N.V. is a clinical-stage biopharmaceutical company specializing in C5a inhibitor development for autoimmune and inflammatory diseases. Their lead candidate, vilobelimab, targets conditions like hidradenitis suppurativa and vasculitis. With a focus on novel therapies, InflaRx operates primarily in Germany and the United States.

What Is the Investment Thesis for IFRX?

InflaRx N.V. presents a high-risk, high-reward investment opportunity centered on its C5a inhibition technology. The primary value driver is the successful development and commercialization of vilobelimab, particularly for hidradenitis suppurativa, where Phase III trials have been completed. Positive clinical trial outcomes for ANCA-associated vasculitis (Phase II) and other indications could significantly boost the company's valuation. However, the company's negative profit and gross margins (-146251.1% and -26390.0%, respectively) highlight the financial risks associated with clinical-stage biopharmaceutical companies. Upcoming clinical trial results and potential regulatory approvals represent key catalysts. The high beta of 1.51 indicates significant volatility. Successful partnerships, like the one with Merck & Co. Inc., could de-risk the investment. Failure to secure regulatory approval or raise additional capital poses significant risks.

Based on FMP financials and quantitative analysis

IFRX Key Highlights

• InflaRx N.V. is a clinical-stage biopharmaceutical company focused on C5a inhibition technology.
• Lead product candidate vilobelimab has completed Phase III clinical trials for hidradenitis suppurativa.
• Vilobelimab is in Phase II trials for ANCA-associated vasculitis and Phase IIa exploratory study for pyoderma gangraenosum.
• The company is developing INF904, an oral, small molecule drug candidate for undisclosed chronic inflammatory and autoimmune diseases.
• InflaRx has a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration with Merck & Co. Inc.

Who Are IFRX's Competitors?

IFRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IFRX's Key Strengths?

• Novel C5a inhibition technology.
• Lead product candidate vilobelimab with promising clinical trial results.
• Experienced management team.
• Strategic partnerships with Beijing Defengrei and Merck & Co. Inc.

What Are IFRX's Weaknesses?

• Clinical-stage company with no approved products.
• High operating losses and negative profit margin.
• Reliance on the success of vilobelimab.
• Limited financial resources.

What Could Drive IFRX Stock Higher?

• Results from Phase II clinical trial of vilobelimab for ANCA-associated vasculitis.
• Initiation of Phase II clinical trial for INF904 in undisclosed chronic inflammatory and autoimmune diseases.
• Continued enrollment and data readout from Phase II clinical development stage for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma.
• Potential regulatory submissions for vilobelimab in hidradenitis suppurativa.

What Are the Key Risks for IFRX?

• Financial-distress signal — its Altman Z-Score of -5.91 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-94.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to obtain regulatory approval for vilobelimab.
• Clinical trial failures or delays.
• Competition from other pharmaceutical companies developing therapies for autoimmune and inflammatory diseases.
• Dependence on key personnel and strategic partnerships.
• Need for additional financing to fund clinical development and commercialization.

What Are the Growth Opportunities for IFRX?

• Expansion into New Indications: Vilobelimab's potential extends beyond its current clinical trials. Exploring its efficacy in other C5a-mediated diseases, such as rheumatoid arthritis or lupus, could significantly broaden its market reach. The market for rheumatoid arthritis treatments alone is projected to reach billions of dollars by 2030. Successful clinical trials in these new areas could drive substantial growth for InflaRx.
• Strategic Partnerships and Acquisitions: Collaborating with larger pharmaceutical companies for late-stage development and commercialization could accelerate vilobelimab's market entry and reduce financial risk. Licensing agreements or even an acquisition by a major player in the autoimmune space could provide InflaRx with the resources and infrastructure needed to maximize its potential. Such partnerships can provide upfront payments, milestone payments, and royalties on future sales.
• Advancement of INF904: The development of INF904, an oral, small molecule drug candidate, represents a significant growth opportunity. Oral medications often have advantages in terms of patient compliance and convenience compared to intravenous therapies like vilobelimab. If INF904 proves effective in clinical trials for chronic inflammatory and autoimmune diseases, it could become a blockbuster drug with a large market share. The timeline for this growth driver depends on the successful completion of preclinical and clinical studies.
• Geographic Expansion: Currently focused on Germany and the United States, InflaRx can expand its market presence to other regions, such as Europe and Asia. These regions have a growing demand for advanced therapies for autoimmune and inflammatory diseases. Entering these markets would require regulatory approvals and potentially partnerships with local distributors, but it could significantly increase InflaRx's revenue potential.
• Orphan Drug Designation and Market Exclusivity: Securing orphan drug designation for vilobelimab in rare diseases like ANCA-associated vasculitis provides market exclusivity and regulatory benefits. This can protect InflaRx's market share from competitors and ensure a longer period of profitability. The orphan drug market is attractive due to higher pricing power and reduced competition, making it a valuable growth driver for InflaRx.

What Opportunities Does IFRX Have?

• Expansion into new indications for vilobelimab.
• Advancement of INF904 and IFX002.
• Strategic collaborations and licensing agreements.
• Orphan drug designation for rare diseases.

What Threats Does IFRX Face?

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from established pharmaceutical companies.
• Patent expiration and biosimilar competition.

What Are IFRX's Competitive Advantages?

• Proprietary C5a inhibition technology.
• Patent protection for vilobelimab and other drug candidates.
• First-in-class anti-C5a monoclonal antibody.
• Clinical trial data demonstrating efficacy in specific indications.

What Does IFRX Do?

InflaRx N.V., founded in 2007 and headquartered in Jena, Germany, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative inhibitors that leverage C5a technology. The company's core focus revolves around addressing the inflammatory mediator C5a, which plays a significant role in the progression of various autoimmune and inflammatory diseases. InflaRx's lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class anti-C5a monoclonal antibody. Vilobelimab has completed Phase III clinical trials for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. Additionally, it is in Phase II trials for anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis, a rare and life-threatening autoimmune disease. The company is also exploring vilobelimab's potential in treating pyoderma gangraenosum, a chronic inflammatory skin disorder, through a Phase IIa exploratory study, and in PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma, which is in Phase II clinical development. Beyond vilobelimab, InflaRx is developing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, currently in the pre-clinical development stage for chronic inflammation and autoimmune diseases. InflaRx collaborates with Beijing Defengrei Biotechnology Co. Ltd. through a co-development agreement and has a clinical trial collaboration and supply agreement with Merck & Co. Inc. Formerly known as Fireman B.V., the company rebranded as InflaRx N.V. in 2017.

What Products and Services Does IFRX Offer?

• Discovers and develops inhibitors using C5a technology.
• Develops vilobelimab, a monoclonal antibody, for autoimmune and inflammatory diseases.
• Conducts clinical trials for hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangraenosum.
• Develops INF904, an oral, small molecule drug candidate for chronic inflammatory and autoimmune diseases.
• Engages in co-development agreements with other biotechnology companies.
• Collaborates with pharmaceutical companies for clinical trials and supply agreements.

How Does IFRX Make Money?

• Develops and patents novel C5a inhibitors.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA and EMA.
• Commercializes approved drugs directly or through partnerships.

What Industry Does IFRX Operate In?

InflaRx N.V. operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy development timelines, and stringent regulatory requirements. The market for autoimmune and inflammatory disease treatments is substantial and growing, driven by an aging population and increased prevalence of these conditions. Competition includes established pharmaceutical companies and other biotech firms developing novel therapies. InflaRx's focus on C5a inhibition provides a differentiated approach, but the company faces challenges in securing regulatory approvals and commercializing its products. The success of vilobelimab will be crucial in determining InflaRx's market position.

Who Are IFRX's Key Customers?

• Patients suffering from autoimmune and inflammatory diseases.
• Hospitals and clinics that administer InflaRx's therapies.
• Pharmaceutical companies through licensing and collaboration agreements.

ROE -95%Key Financial Metrics

Return on equity for InflaRx N.V. stands at -94.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -87.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -29.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -43.0%, the inverse of the P/E and a quick read on earnings relative to price.

InflaRx N.V. (IFRX) Valuation Context

Valued at $151.33M, IFRX is classified as a micro-cap stock. Relative to its peer group, IFRX's quantitative score of 48/100 is below the peer average of 81/100.

Company Profile

InflaRx N.V. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Jena, DE. The company is led by CEO Niels C. Riedemann. IFRX has traded publicly since 2017.

F-Score 1/9Financial Health

InflaRx N.V.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.91 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project InflaRx N.V. revenue of about $16K for fiscal 2026, with EPS near $-0.30. The estimate reflects 4 contributing analysts.

IFRX Financials

IFRX Latest News

IFRX Analyst Consensus

IFRX MoonshotScore

InflaRx N.V. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources